Factors Underlying the Difference in Response to Fecal Microbiota Transplantation Between IBS Patients with Severe and Moderate Symptoms

Dig Dis Sci. 2024 Apr;69(4):1336-1344. doi: 10.1007/s10620-024-08369-x. Epub 2024 Mar 6.


Background: Previous studies showed that patients with Severe IBS respond better to fecal microbiota transplantation (FMT) than do those with Moderate IBS.

Aims: The present study aimed to determine the effects of the transplant dose, route of administering it and repeating FMT on this difference.

Methods: This study included 186 patients with IBS randomized 1:1:1 into groups with a 90-g transplant administered once to the colon (LI), once to the duodenum (SI), or twice to the distal duodenum twice (repeated SI). The patients provided a fecal sample and were asked to complete three questionnaires at baseline and at 3, 6, and 12 months after FMT. The fecal bacteria composition and Dysbiosis index were analyzed using 16 S rRNA gene PCR DNA amplification/probe hybridization covering regions V3-V9.

Results: There was no difference in the response rates between severe IBS and moderate IBS for SI and repeated SI at all observation intervals after FMT. In the LI group, the response rate at 3 months after FMT was higher for moderate IBS than for severe IBS. The levels of Dorea spp. were higher and those of Streptococcus salivarius subsp. Thermophilus, Alistipes spp., Bacteroides and Prevotella spp., Parabacteroides johnsoni and Parabacteroides spp. were lower in moderate IBS than in severe IBS.

Conclusions: There was no difference in the response to FMT between severe and moderate IBS when a 90-g transplant was administered to the small intestine. The difference in the bacterial profile between severe and moderate IBS may explain the difference in symptoms between these patients. ( www.

Clinicaltrials: gov : NCT04236843).

Keywords: Alistipes spp; Dorea spp; Parabacteroides johnsoni; Prevotella spp; Fatigue.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Duodenum
  • Fecal Microbiota Transplantation
  • Feces / microbiology
  • Gastrointestinal Microbiome* / physiology
  • Humans
  • Irritable Bowel Syndrome* / diagnosis
  • Treatment Outcome

Associated data

  • ClinicalTrials.gov/NCT04236843